Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review.

Myriam DrysdaleMehmet BerktasDaniel C GibbonsCatherine RollandLouis LavoieEmily J Lloyd

Published in: Infection (2024)

This systematic literature review suggests continued effectiveness of sotrovimab in preventing severe clinical outcomes during BA.2 and BA.5 predominance, both against active/untreated comparators and compared with BA.1 predominance.

Keyphrases

randomized controlled trial
systematic review
case report
early onset